Infection prevention and control measures for Ebola virus disease
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Strengthening health-system emergency preparedness.
REGULATION (EU) No 604/2013 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 26 June 2013 establishing the criteria and mechanisms for determining the Member State responsible for examining an application for international protection lodged in one of the Member States by a third-country national or... a stateless person (recast)
more
Die Verordnung (EU) Nr. 604/2013 des Europäischen Parlaments und des Rates vom 26. Juni 2013 ist eine Verordnung der Europäischen Union, nach der der Mitgliedstaat bestimmt wird, der für die Durchführung eines Asylverfahrens zuständig ist. Die Verordnung tritt an die Stelle der Dublin-II-Verord...nung und wird auch Dublin-III-Verordnung genannt. Sie ist am 19. Juli 2013 in Kraft getreten und ist ihrem Art. 49 zufolge ab dem 1. Januar 2014 unmittelbar anzuwenden.
Andere Sprachversionen verfügbar siehe http://eur-lex.europa.eu/legal-content/DE/TXT/?qid=1445167987946&uri=CELEX:32013R0604
more
This report aims to estimate the economic cost of providing regular access to healthcare for migrants in an irregular situation, compared with the cost of providing treatment in emergency cases only. Two specific medical conditions – hypertension and prenatal care – were selected as examples, an...d their associated costs were calculated using an economic model. This model was then applied to three EU Member States: Germany, Greece and Sweden. The testing suggests that providing access to regular preventive healthcare for migrants in an irregular situation
would be cost-saving for governments.
more
This document aims to present an algorithm for deciding whom to test and provide guidance on the laboratory tests for Zika virus infection diagnosis in order to support clinical diagnostic and case reporting through surveillance among EU Member States. The algorithm is not intended for clinical man...agement of patients with suspected Zika virus infection.
The information is provisional and subject to revision when new information becomes available.
more
The threat posed by Zika virus infection highlights the need to reinforce preparedness arrangements for mosquito-borne diseases in EU/EEA countries, especially for pathogens transmitted by Aedes aegypti and Aedes albopictus.
The aim of this document is to highlight measures that can effectively red...uce the risk of importation and local transmission of pathogens transmitted by Ae. aegypti and Ae. albopictus. The main diseases of concern in this context are Zika, dengue, chikungunya and yellow fever.
more
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiolgists and health professionals on active public health threats. This issue covers the period 7-13 August 2016 and includes updates on Zika virus, yellow fever in Angola, polio, MERS CoV and West Nile virus.
Irresponsible pharmaceutical companies fuel the proliferation of superbugs through supply chain pollution, the European Public Health Alliance (EPHA) reports. The advocacy group uncovered lapses such as dirty production and inadequate waste disposal in the production of antimicrobials in China and I...ndia, which supplies most of the antimicrobials consumed in Europe. In a briefing detailing the pollution, the EPHA urges major purchasers of antibiotics to blacklist irresponsible pharmaceutical companies, demand that the industry clean up its supply chain, introduce greater transparency on the origin of antibiotics, and review and revise procurement policies from an ethics perspective.
more
The checklist tool described in this handbook is intended for EU/EEA public health authorities who need to assess the capacity for communicable disease prevention and control at migrant reception/detention centres hosting migrants for weeks/months (medium-term) in order to identify gaps and set prio...rities for development.
Using this tool, the aim is to monitor and support capacity development to prevent the onset and improve the management of communicable disease outbreaks at medium-term migration reception/detention centres, both on a day-to-day basis and in the event of a sudden influx of migrants.
more
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 5-11 November 2017 and includes updates on measles, rubella, chikungunya, West Nile virus, Plague, monkeypox, legionnair...es's disease, influenza and Marburg virus disease.
more
The Knowledge Centre on Migration and Demography (KCMD) Data Catalogue is a table of data sources relevant to Migration and Demography policies. Each data source is listed with its summary description, the link to its web site and other metadata. The catalogue will include official EU and internatio...nal statistics, as well as important data sets at Member State level.
more